Airway inflammation and eotaxin in exhaled breath condensate of patients with severe persistent allergic asthma during omalizumab therapy

Ziętkowski, Ziemowit; Skiepko, Roman; Tomasiak-Lozowska, M M; Bodzenta-Łukaszyk, Anna

doi:10.2478/v10039-011-0024-0

Cited by 19 publications

(16 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Elevated levels of ECP have been observed in asthmatics. Additionally, there is an association between increased ECP concentrations and asthma aggravation as a biomarker (23,24). We observed a correlation between ECP and FeNO and FeNO and age in the pretreatment group (Group IA) in our study.…”

Section: Discussionsupporting

confidence: 59%

Effects of Omalizumab Treatment on Some Biomarkers in Severe Allergic Asthma Patients

Önür¹,

Yalçın²,

Gümüşlü³

et al. 2017

Eurasian J Pulmonol

View full text Add to dashboard Cite

Objective: The mechanism of biological treatment molecule called omalizumab used in asthma treatment is thought to be versatile; however, the mechanism still remains unknown. This study was undertaken in severe asthma patients underwent omalizumab treatment, in order to investigate the relationship between biomarker expression and disease characteristics related to the immune system. Methods:Consecutive patients with severe asthma disease (n=15; Group IA, pretreatment and Group IB, post-treatment) underwent omalizumab treatment. Control group was age-and sex-matched including 25 healthy in Group II. Blood samples from both the groups were taken during their first visit (Group IA and II) and then after 12 months of treatment in asthmatic patients (Group IB). Serum levels of homocysteine (Hcy), eosinophil cationic peptide (ECP), 25-hydroxyvitamin D (25(OH)D), interleukin-1β (IL-1β), soluble OX 2 (sCD200) and clinical follow-up tests including fractional exhaled nitric oxide (FeNO), asthma control test (ACT), and pulmonary function tests were evaluated.Results: After the treatment, 25(OH)D levels and pulmonary function tests, including forced expiratory volume in 1 second (FEV 1 ) and forced vital capacity (FVC) levels, were significantly increased. Furthermore, total immunoglobulin E (IgE), Hcy, ECP, FeNO, and sCD200 levels were dramatically diminished. Regression analysis revealed positive correlations between ACT-FEV 1 and ACT-FVC and between FeNO-age and FeNO-ECP for Group IA patients. Negative correlations were detected between ACT-IgE, age-FEV 1 , FeNO-FEV 1 , and Fe-NO-FVC for Group IA patients. Conclusion:Our results suggest that the potential use of serum biomolecules in concordance to the clinical status of the asthmatic patients might be a follow-up tool for the omalizumab therapy.

show abstract

Section: Discussionsupporting

confidence: 59%

Effects of Omalizumab Treatment on Some Biomarkers in Severe Allergic Asthma Patients

Önür¹,

Yalçın²,

Gümüşlü³

et al. 2017

Eurasian J Pulmonol

View full text Add to dashboard Cite

show abstract

“…A similar effect was observed for FeNO and serum periostin levels, which are considered biomarkers for eosinophilic airway inflammation. Zietkowski et al [55] also showed a significant decrease in the peripheral eosinophil count, ECP level and FeNO level, which correlated with a decrease in eotaxin levels in the exhaled breath condensate in patients with asthma, who were treated with omalizumab. Whereas Skiepko et al [56] observed that a decrease in the peripheral eosinophil number by 50% under the influence of the treatment with omalizumab compared to baseline was associated with a lower frequency of severe exacerbations than in the group with a smaller reduction in the number of eosinophils.…”

Section: The Impact Of Omalizumab On Eosinophilia In Asthma Patients mentioning

confidence: 89%

“…Chemotactic factors are responsible for the influx of eosinophils to the site of inflammatory reaction. The study by Zietkowki et al revealed that omalizumab therapy reduces the level of eotaxin [55] and RANTES [90] -strong chemoattractants for eosinophils -in the air exhausted by patients with allergic asthma.…”

Section: Mechanisms Of Omalizumab Effect On Eosinophilsmentioning

confidence: 99%

“…NO inhibits apoptosis dependent on the activation of the Fas receptor [93]. Increased levels of NO are observed in asthma, while omalizumab therapy significantly reduces the NO concentration in the exhaled air [28,34,53,55,56], which may be important for regression of eosinophilic inflammation in the airways.…”

Section: Mechanisms Of Omalizumab Effect On Eosinophilsmentioning

confidence: 99%

See 1 more Smart Citation

The Effect of Omalizumab on Eosinophilic Inflammation of the Respiratory Tract in Patients with Allergic Asthma

Kupryś‐Lipińska¹,

Molińska²,

Kuna³

2016

Advances in Respiratory Medicine

View full text Add to dashboard Cite

Bronchial asthma is characterised by high levels of immunoglobulin E (IgE) and overproduction of pro-inflammatory cytokines, including interleukins IL-4, IL-13 and IL-5 needed for, amongst other things, the production of IgE and the differentiation, maturation, migration and survival of eosinophils. Eosinophils are one of the most important cells in allergic inflammation. Their presence in tissue is linked to the persistence of inflammatory infiltrate, tissue damage and remodelling. Although these cells are very sensitive to corticosteroids, some asthmatic patients do not respond to high doses of these drugs, even when administered systemically. Transbronchial biopsies and bronchoalveolar lavage performed in patients with steroid-resistant asthma have demonstrated higher levels of eosinophils and Th2-type cytokines (IL-4 and IL-5) compared to steroid-sensitive patients. Clinical studies have confirmed that the very effective treatment in these cases is therapy with omalizumab -an anti-IgE monoclonal antibody. The paper discusses the efficacy of omalizumab in reducing eosinophil number in peripheral blood and in the airways of asthmatic patients based on basic, clinical, observational studies and case reports. The significance of omalizumab therapy in asthma control and mechanisms that regulate the effects of omalizumab on eosinophils are evaluated.

show abstract

“…Patients with uncontrolled asthma showed higher CCL-11 levels compared to stabilized asthmatic patients (130). Furthermore, reduction in CCL-11 levels after omalizumab treatment among patients with severe asthma reflected remission of eosinophilic inflammation (131). The degree of airway hyper-responsiveness correlates with macrophage activation markers such as CD14, CD16, CD18, CD29, CD32, HLA class I and HLA DQ (132).…”

Section: Surrogate Biomarkers For Lung Functionmentioning

confidence: 98%

Current and future biomarkers in allergic asthma

Zissler

Bieren

Jakwerth

et al. 2016

Allergy

107

View full text Add to dashboard Cite

Diagnosis early in life, sensitization, asthma endotypes, monitoring of disease and treatment progression are key motivations for the exploration of biomarkers for allergic rhinitis and allergic asthma. The number of genes related to allergic rhinitis and allergic asthma increases steadily; however, prognostic genes have not yet entered clinical application. We hypothesize that the combination of multiple genes may generate biomarkers with prognostic potential. The current review attempts to group more than 161 different potential biomarkers involved in respiratory inflammation to pave the way for future classifiers. The potential biomarkers are categorized into either epithelial or infiltrate-derived or mixed origin, epithelial biomarkers. Furthermore, surface markers were grouped into cell-typespecific categories. The current literature provides multiple biomarkers for potential asthma endotypes that are related to T-cell phenotypes such as Th1, Th2, Th9, Th17, Th22 and Tregs and their lead cytokines. Eosinophilic and neutrophilic asthma endotypes are also classified by epithelium-derived CCL-26 and osteopontin, respectively. There are currently about 20 epithelium-derived biomarkers exclusively derived from epithelium, which are likely to innovate biomarker panels as they are easy to sample. This article systematically reviews and categorizes genes and collects current evidence that may promote these biomarkers to become part of allergic rhinitis or allergic asthma classifiers with high prognostic value.

show abstract

Airway inflammation and eotaxin in exhaled breath condensate of patients with severe persistent allergic asthma during omalizumab therapy

Cited by 19 publications

References 25 publications

Effects of Omalizumab Treatment on Some Biomarkers in Severe Allergic Asthma Patients

Effects of Omalizumab Treatment on Some Biomarkers in Severe Allergic Asthma Patients

The Effect of Omalizumab on Eosinophilic Inflammation of the Respiratory Tract in Patients with Allergic Asthma

Current and future biomarkers in allergic asthma

Contact Info

Product

Resources

About